In recent years, with the introduction of innovative drug support policies and the increase in R&D investment, the innovative drug market has developed rapidly, and the proportion of innovative drugs launched in mainland China has been increasing. The participation of Chinese pharmaceutical companies in global clinical R&D has been increasing, and the proportion of first-time innovative drugs has increased from 14% in 2016 to 29% in 2023, showing an increasing trend.
Data source: Pharmaceutical Rubik's Cube, compiled by China Business Industry Research Institute
In 2023, there will be a total of 184 innovative drugs launched for the first time in the world, of which 54 will be launched in China, accounting for 29%.
Data source: Pharmaceutical Rubik's Cube, compiled by China Business Industry Research Institute
For more information, please refer to the "Research Report on China's Innovative Drug Market Prospects and Investment Opportunities" released by the China Commercial Industry Research Institute, and the China Commercial Industry Research Institute also provides industrial big data, industrial intelligence, industry research reports, industry white papers, industry status certificates, feasibility study reports, industrial planning, industrial chain investment map, industrial investment guidelines, industrial chain investment investigation & promotion meeting, "15th Five-Year Plan" and other consulting services.